monoclonal antibody therapies
What would an ideal target look like for a therapeutic antibody e.g. in cancer therapy?
What would be factors contributing to enhanced biological activity in terms of antigen binding?
Would recognition and binding of the antibody to the target antigen sufficient to
a. prevent virus binding to body cells?
b. elimination of cancer cells?
antibodys
steckbrief
Pentameric IgM
FcRn-Fo receptor
effector functions of IgG
effector functions (2)
complementkey functions:
Ig glycosylation on FurR binding
Antibody summary
4. Designing an „ideal“ Fc domain for a therapeutic antibody. What changes could be introduced to
a. enhance in vivo half-life?
b. abrogate Fc receptor and complement binding?
c. enhance Fc receptor binding?
d. enhance complement activation?
The route of application is another factor potentially affecting in vivo activity. How could one achieve enhanced antibody levels in the mucosa to e.g. improve anti-viral activity?
Can glycosylated IgG antibodies be produced in bacteria or yeast? Why/why not?
Last changeda year ago